As India steps into 2026, the life sciences sector stands at a transformative crossroads—poised not just for growth in scale, but for a leap toward ...

The rising prevalence of diabetes has transformed it from a lifestyle disorder into a major public health challenge in India. With millions of new cas...

India’s pharmaceutical regulatory landscape is bracing for a major shift as the Drugs Controller General of India (DCGI) confirmed that the revised ...

Chandigarh has rapidly emerged as one of the most preferred destinations for pharmaceutical business expansion in North India. With its well-planned i...

The pharmaceutical sector has long been a battleground of opportunity for investors looking to balance stability with growth potential. With both Indi...

India has long been celebrated as the “pharmacy of the world,” supplying affordable generic medicines to nearly every corner of the globe. Yet ben...

When the US regulator US Food and Drug Administration (US FDA) formally accepted the New Drug Application (NDA) for Zaynich — a novel antibiotic dev...

India’s relationship with diabetes has long been a complicated one. With more than 100 million people currently living with the condition, the natio...

India is aiming to shift its pharmaceutical narrative — and the Centre’s recent decision to extend the deadline for its ₹5,000 crore R&D sc...